Level D· Scientific groundwork from lab and animal studiesNarrative ReviewEurope PMCOpen access

Regenerative therapies for refractory thin endometrium in <i>in vitro</i> fertilization

Chen HJ., Chen MJ., Chang PH., Lu YT., Hsueh YW., Chang CW.

Narrative Review on Systemic / IV, published in Front Cell Dev Biol (2025) — summary generated from the PubMed abstract.

Open my reading list
Level D· Scientific groundwork from lab and animal studiesEvidence level of this study

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Narrative Review
Journal
Front Cell Dev Biol (2025)
Reported sample size
—
Source database
Europe PMC
PMID
41210253
PMCID
PMC12592153
DOI
10.3389/fcell.2025.1668960

Abstract (original English)

Refractory thin endometrium remains a significant challenge in assisted reproductive technology, frequently leading to poor endometrial receptivity and suboptimal outcomes in in vitro fertilization (IVF) cycles. In recent years, regenerative therapies such as platelet-rich plasma (PRP), granulocyte colony-stimulating factor (G-CSF), growth hormone (GH), and stem cell-based interventions, have gained increasing attention as promising strategies to enhance endometrial function and receptivity. Notably, growing interest has also focused on the therapeutic potential of stem cell-derived exosomes in facilitating endometrial repair, although clinical evidence remains limited. Recent studies suggest that regenerative interventions are administered either locally, via intrauterine infusion or sub-endometrial injection, or systemically at various stages of the IVF protocol. Among these approaches, PRP and G-CSF have shown consistent benefits in increasing endometrial thickness and improving clinical pregnancy rates, particularly in frozen embryo transfer cycles. GH has been associated with enhanced endometrial proliferation, while stem cell-based therapies, particularly those utilizing mesenchymal or bone marrow-derived stem cells, demonstrate potential to restore severely damaged endometrial tissue. In preclinical models, stem cell-derived exosomes have been shown to promote endometria

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.
  • • This is a narrative review: it collects no new patient data and does not systematically appraise evidence quality.

Evidence level

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

How we grade evidence

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research